한글목차

당뇨병 치료 약물 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 734억 8,000만 달러에서 2026년에는 775억 7,000만 달러로, CAGR 5.6%로 확대될 것으로 예상됩니다. 지난 수년간의 성장에는 첨단 인슐린 제제의 공급 제한, 당뇨병 관리에 대한 인식 제고, 헬스케어 인프라 확충, 경구용 당뇨병 치료 약물 의존도 증가, 제2형 당뇨병 유병률 증가 등이 주요 요인으로 작용한 것으로 보입니다.

당뇨병 치료 약물 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 951억 3,000만 달러에 달하고, CAGR은 5.2%가 될 전망입니다. 예측 기간의 성장 요인으로는 신규 GLP-1 수용체 작용제 개발, SGLT-2 억제제 채택 확대, 주사제 및 흡입제 선택권 확대, 재택 당뇨병 치료의 성장, 디지털 건강 모니터링 시스템 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 전 세계 당뇨병 유병률 증가, 병용요법 증가, 개별화된 당뇨병 관리의 성장, 전문 약국 및 병원 유통 채널 확대, 서방형 및 환자 친화적 제형에 대한 집중 등이 있습니다.

당뇨병 환자의 증가는 향후 몇 년 동안 당뇨병 치료 약물 시장의 성장을 견인할 것으로 예상됩니다. 당뇨병 환자란 혈당 조절 기능에 영향을 미치는 장기적인 대사 장애인 당뇨병 진단을 받은 사람들을 말합니다. 당뇨병 환자의 증가는 주로 비만과 인슐린 저항성을 유발하는 건강에 해로운 식습관과 운동 부족의 생활습관에 기인합니다. 당뇨병 치료 약물은 환자가 혈당을 효과적으로 관리하는 데 중요한 역할을 하며, 제1형 및 제2형 당뇨병 치료에 필수적입니다. 이러한 약물은 혈당을 안정적으로 유지하여 합병증을 예방하고 전반적인 건강을 지원하며 삶의 질을 향상시키는 데 도움을 줍니다. 예를 들어, 영국 정부 기관인 국민보건서비스(NHS)에 따르면 2024년 6월 기준, 2023년 일반 개업의에 등록된 환자 중 3,615,330명이 비당뇨병성 고혈당 또는 전당뇨병으로 진단을 받았습니다. 이는 2022년 3,065,825건에서 18% 증가한 수치입니다. 따라서 당뇨병 환자 수의 증가는 당뇨병 치료 약물 시장의 성장을 촉진하고 있습니다.

당뇨병 치료 약물 시장에서 사업을 전개하는 주요 기업들은 혈당 조절 개선, 환자 복약 순응도 향상, 치료 계획 간소화를 목표로 고정 비율 배합 요법 등 첨단 치료법 개발에 주력하고 있습니다. 고정비율 복합요법은 두 가지의 상호보완적인 항당뇨병제를 한 번의 주사로 결합하여 당뇨병 관리에 있어 보다 편리하고 효과적인 접근법을 제공합니다. 예를 들어, 2024년 4월 프랑스 제약사 사노피 SA는 제2형 당뇨병과 비만을 동반한 성인을 위해 설계된 인슐린 글라진과 릭시세나티드의 1일 1회 투여 고정 비율 복합제 '솔리쿠아'를 출시하였습니다. 솔리쿠아는 안정적인 공복혈당 조절을 위한 장시간 지속형 인슐린 글라스랄진과 GLP-1 수용체 작용제인 릭시세나티드를 통합한 제품입니다. 이 제제는 포도당 의존성 인슐린 분비를 촉진하고, 글루카곤 방출을 억제하며, 위 내용물 배출을 지연시켜 식후 혈당을 낮추어 종합적인 주간 혈당 조절을 실현합니다. 솔리쿠아의 출시는 여러 번의 주사 횟수를 줄이고 저혈당, 체중 증가 등의 부작용을 억제하여 당뇨병 관리의 효율화, 혈당 조절 개선, 환자의 복약 순응도 향상을 목표로 하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Diabetes care drugs are medications prescribed to control blood glucose levels in people with diabetes mellitus, including type 1 diabetes, type 2 diabetes, and gestational diabetes. These drugs act by increasing insulin production, improving insulin sensitivity, or decreasing glucose absorption in the body. Their primary objective is to maintain healthy blood sugar levels and prevent diabetes-related complications.

The main drug classes in diabetes care drugs include insulin, biguanides, sulfonylureas, dipeptidyl peptidase (DPP)-4 inhibitors, sodium-glucose co-transporter (SGLT)-2 inhibitors, glucagon-like peptide (GLP)-1 receptor agonists, thiazolidinediones, and alpha-glucosidase inhibitors. Insulin is a pharmaceutical form of the naturally occurring hormone that is administered by injection or inhalation to supplement inadequate insulin production or utilization in the body. These medications are available in multiple formulation types, including tablets, injections, solutions, gels, and extended-release formulations. They are administered through oral, injectable, and inhalable routes and are mainly used for the management of type 1 and type 2 diabetes. Distribution channels include hospital pharmacies and specialty pharmacies.

Tariffs have affected the diabetes care drugs market by increasing costs for imported active pharmaceutical ingredients (APIs) and specialized delivery devices. Segments such as GLP-1 receptor agonists, SGLT-2 inhibitors, and insulin formulations are most impacted, particularly in regions like North America and Asia-Pacific where imports are significant. This has resulted in higher treatment costs and supply chain adjustments. However, tariffs also encourage local manufacturing, investment in domestic production capacities, and the development of cost-optimized formulations.

The diabetes care drugs market research report is one of a series of new reports from The Business Research Company that provides diabetes care drugs market statistics, including diabetes care drugs industry global market size, regional shares, competitors with a diabetes care drugs market share, detailed diabetes care drugs market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes care drugs industry. This diabetes care drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The diabetes care drugs market size has grown strongly in recent years. It will grow from $73.48 billion in 2025 to $77.57 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to limited availability of advanced insulin formulations, growing awareness of diabetes management, rising healthcare infrastructure, dependence on oral antidiabetic drugs, increasing incidence of type 2 diabetes.

The diabetes care drugs market size is expected to see strong growth in the next few years. It will grow to $95.13 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel GLP-1 receptor agonists, adoption of SGLT-2 inhibitors, expansion of injectable and inhalable drug options, growth in home-based diabetes care, integration of digital health monitoring systems. Major trends in the forecast period include rising prevalence of diabetes worldwide, increased adoption of combination therapies, growth in personalized diabetes management, expansion of specialty pharmacies and hospital distribution channels, focus on extended-release and patient-friendly formulations.

The growing number of diabetic patients is anticipated to drive the expansion of the diabetes care drugs market in the coming years. Diabetic patients are individuals diagnosed with diabetes mellitus, a long-term metabolic disorder that affects the body's ability to regulate blood glucose levels. The rise in the diabetic population is largely attributed to unhealthy dietary habits and sedentary lifestyles, which contribute to obesity and insulin resistance. Diabetes care drugs play a critical role in helping patients effectively manage blood sugar levels, making them essential for the treatment of both type 1 and type 2 diabetes. These medications help prevent complications by maintaining stable glucose levels, supporting overall health, and improving quality of life. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner were identified with non-diabetic hyperglycemia or pre-diabetes in 2023, representing an 18% increase from 3,065,825 cases in 2022. Therefore, the rising number of diabetic patients is fueling the growth of the diabetes care drugs market.

Major companies operating in the diabetes care drugs market are concentrating on the development of advanced treatment options, such as fixed-ratio combination therapies, to improve glycemic control, boost patient adherence, and simplify treatment plans. Fixed-ratio combination therapies are medications that combine two complementary antidiabetic agents into a single injection, providing a more convenient and effective approach to diabetes management. For instance, in April 2024, Sanofi SA, a France-based pharmaceutical company, introduced Soliqua, a once-daily fixed-ratio combination of insulin glargine and lixisenatide designed for adults with type 2 diabetes and obesity. Soliqua integrates long-acting insulin glargine, which delivers consistent fasting glucose control, with lixisenatide, a GLP-1 receptor agonist. This formulation enhances glucose-dependent insulin secretion, reduces glucagon release, and slows gastric emptying to lower postprandial blood glucose levels, offering comprehensive daily glycemic regulation. The launch of Soliqua is intended to streamline diabetes management, enhance glycemic outcomes, and improve patient adherence by reducing the need for multiple injections and limiting side effects such as hypoglycemia and weight gain.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired certain anti-diabetes trademarks from Boehringer Ingelheim International GmbH for an undisclosed sum. Through this acquisition, Lupin obtained full trademark ownership of GIBTULIO, GIBTULIO MET, and AJADUO, allowing the company to independently market and integrate these oral antidiabetic medicines across India, thereby strengthening and expanding its diabetes care portfolio. Boehringer Ingelheim International GmbH is a Germany-based pharmaceutical company specializing in the development and manufacture of diabetes care drugs.

Major companies operating in the diabetes care drugs market are Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Wockhardt, Mitsubishi Tanabe Pharma, Gan & Lee Pharmaceuticals, Apotex.

North America was the largest region in the diabetes care drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes care drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the diabetes care drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diabetes care drugs market consists of sales of oral antidiabetic drugs, non-insulin injectable drugs, and combination drugs. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Diabetes Care Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses diabetes care drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for diabetes care drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes care drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Insulin; Biguanides; Sulfonylureas; Dipeptidyl Peptidase (DPP)-4 Inhibitors; Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors; Glucagon-Like Peptide (GLP)-1 Receptor Agonists; Thiazolidinediones; Alpha-Glucosidase Inhibitors
• 2) By Formulation Type: Tablets; Injections; Solutions; Gels; Extended-Release Formulations
• 3) By Administration Route: Oral; Injectable; Inhalable
• 4) By Condition: Diabetes Type 1; Diabetes Type 2
• 5) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
• Subsegments:
• 1) By Insulin: Rapid-acting insulin; Short-acting insulin; Intermediate-acting insulin; Long-acting insulin; Pre-mixed insulin
• 2) By Biguanides: Metformin Immediate Release (IR); Metformin Extended Release (ER)
• 3) By Sulfonylureas: First-generation sulfonylureas; Second-generation sulfonylureas
• 4) By Dipeptidyl Peptidase (DPP)-4 Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
• 5) By Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin
• 6) By Glucagon-Like Peptide (GLP)-1 Receptor Agonists: Exenatide; Liraglutide; Dulaglutide; Semaglutide; Lixisenatide
• 7) By Thiazolidinediones (TZDs): Pioglitazone; Rosiglitazone
• 8) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
• Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Eli Lilly and Company; Teva Pharmaceuticals Limited; Astellas Pharma Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Dr. Reddy's Laboratories; Cipla Limited; Lupin Limited; Takeda Pharmaceutical Company Limited; Biocon Limited; Glenmark Pharmaceuticals Limited; Torrent Pharmaceuticals Ltd.; Hanmi Pharmaceutical Limited; Wockhardt; Mitsubishi Tanabe Pharma; Gan & Lee Pharmaceuticals; Apotex.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Diabetes Care Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Diabetes Care Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Diabetes Care Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Diabetes Care Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Diabetes Worldwide
  • 4.2.2 Increased Adoption Of Combination Therapies
  • 4.2.3 Growth In Personalized Diabetes Management
  • 4.2.4 Expansion Of Specialty Pharmacies And Hospital Distribution Channels
  • 4.2.5 Focus On Extended-Release And Patient-Friendly Formulations

5. Diabetes Care Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Pharmacies
• 5.3 Clinics And Healthcare Centers
• 5.4 Home Healthcare Providers
• 5.5 Research And Academic Institutions

6. Diabetes Care Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Diabetes Care Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Diabetes Care Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Diabetes Care Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Diabetes Care Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Diabetes Care Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Diabetes Care Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Diabetes Care Drugs Market Segmentation

• 9.1. Global Diabetes Care Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Insulin, Biguanides, Sulfonylureas, Dipeptidyl Peptidase (DPP)-4 Inhibitors, Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors, Glucagon-Like Peptide (GLP)-1 Receptor Agonists, Thiazolidinediones, Alpha-Glucosidase Inhibitors
• 9.2. Global Diabetes Care Drugs Market, Segmentation By Formulation Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablets, Injections, Solutions, Gels, Extended-Release Formulations
• 9.3. Global Diabetes Care Drugs Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable, Inhalable
• 9.4. Global Diabetes Care Drugs Market, Segmentation By Condition, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diabetes Type 1, Diabetes Type 2
• 9.5. Global Diabetes Care Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Specialty Pharmacies
• 9.6. Global Diabetes Care Drugs Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rapid-acting insulin, Short-acting insulin, Intermediate-acting insulin, Long-acting insulin, Pre-mixed insulin
• 9.7. Global Diabetes Care Drugs Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Metformin Immediate Release (IR), Metformin Extended Release (ER)
• 9.8. Global Diabetes Care Drugs Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• First-generation sulfonylureas, Second-generation sulfonylureas
• 9.9. Global Diabetes Care Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase (DPP)-4 Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
• 9.10. Global Diabetes Care Drugs Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter (SGLT)-2 Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
• 9.11. Global Diabetes Care Drugs Market, Sub-Segmentation Of Glucagon-Like Peptide (GLP)-1 Receptor Agonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
• 9.12. Global Diabetes Care Drugs Market, Sub-Segmentation Of Thiazolidinediones (TZDs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pioglitazone, Rosiglitazone
• 9.13. Global Diabetes Care Drugs Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Acarbose, Miglitol

10. Diabetes Care Drugs Market Regional And Country Analysis

• 10.1. Global Diabetes Care Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Diabetes Care Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Diabetes Care Drugs Market

• 11.1. Asia-Pacific Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Diabetes Care Drugs Market

• 12.1. China Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Diabetes Care Drugs Market

• 13.1. India Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Diabetes Care Drugs Market

• 14.1. Japan Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Diabetes Care Drugs Market

• 15.1. Australia Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Diabetes Care Drugs Market

• 16.1. Indonesia Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Diabetes Care Drugs Market

• 17.1. South Korea Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Diabetes Care Drugs Market

• 18.1. Taiwan Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Diabetes Care Drugs Market

• 19.1. South East Asia Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Diabetes Care Drugs Market

• 20.1. Western Europe Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Diabetes Care Drugs Market

• 21.1. UK Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Diabetes Care Drugs Market

• 22.1. Germany Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Diabetes Care Drugs Market

• 23.1. France Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Diabetes Care Drugs Market

• 24.1. Italy Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Diabetes Care Drugs Market

• 25.1. Spain Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Diabetes Care Drugs Market

• 26.1. Eastern Europe Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Diabetes Care Drugs Market

• 27.1. Russia Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Diabetes Care Drugs Market

• 28.1. North America Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Diabetes Care Drugs Market

• 29.1. USA Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Diabetes Care Drugs Market

• 30.1. Canada Diabetes Care Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Diabetes Care Drugs Market

• 31.1. South America Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Diabetes Care Drugs Market

• 32.1. Brazil Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Diabetes Care Drugs Market

• 33.1. Middle East Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Diabetes Care Drugs Market

• 34.1. Africa Diabetes Care Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Diabetes Care Drugs Market, Segmentation By Drug Class, Segmentation By Formulation Type, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Diabetes Care Drugs Market Regulatory and Investment Landscape

36. Diabetes Care Drugs Market Competitive Landscape And Company Profiles

• 36.1. Diabetes Care Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Diabetes Care Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Diabetes Care Drugs Market Company Profiles
  • 36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

37. Diabetes Care Drugs Market Other Major And Innovative Companies

• AstraZeneca plc, Eli Lilly and Company, Teva Pharmaceuticals Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Cipla Limited, Lupin Limited, Takeda Pharmaceutical Company Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Hanmi Pharmaceutical Limited, Wockhardt

38. Global Diabetes Care Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Diabetes Care Drugs Market

40. Diabetes Care Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Diabetes Care Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Diabetes Care Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Diabetes Care Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer